Clinical Features, Laboratory Investigations, and Survival in Ocular Reticulum Cell Sarcoma

Primary Intraocular Lymphoma

“…These are estimated to represent 4e6% of primary brain tumors and 1e2% of extranodal lymphomas. 85,106 The incidence in the USA has tripled over the past 15 years, 72,106,177 and this rise has been mirrored in Europe. 123 This increase was initially thought to be due to increased numbers of immunocompromised patients, but since the introduction of highly active antiretroviral therapy, the incidence in patients with the acquired immune deficiency syndrome (AIDS) has declined.…”

“…163,183 The mean age of presentation is in the fifth and sixth decades of life. 19,51,85,163,213 Some reports suggest a sex bias, with women more commonly affected than men by 2:1 15,21,163 or even greater. 27,168 More recently there appears to have been an increase of reported 6 cases in men.…”

“…27,80,104 Conversely, it is estimated that between 42% and 92% of PIOL cases go on to exhibit intracranial lymphoma within a mean interval of 8e29 months. 2,27,51,85,163 Widespread dissemination of PCNSL can also occur in 7e8% of patients, usually late in the course. 104 …”

Intraocular rituximab

“…1 The most common ophthalmologic manifestations are vitritis and subretinal pigment epithelial infiltrates. [2][3][4] Intraocular involvement may be a presenting feature with subsequent central nervous system (CNS) involvement in 56-85% of patients over a period of many months to several years. 2,5,6 Conversely, about 20% of patients with PCNSL have concurrent intraocular involvement.…”

“…[2][3][4] Intraocular involvement may be a presenting feature with subsequent central nervous system (CNS) involvement in 56-85% of patients over a period of many months to several years. 2,5,6 Conversely, about 20% of patients with PCNSL have concurrent intraocular involvement. 3,4 Management of PCNSL is still evolving and any treatment for ocular involvement should be undertaken in conjunction with an oncologist.…”